Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
The initiative aims to encourage women and parents to seek timely medical guidance on cervical cancer prevention and HPV awareness
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
Lifts full-year outlook as obesity drug boom accelerates
But acquisition charges drag earnings into loss
The summit will bring together 1,200+ delegates, 100+ international faculty from 25 countries
Subscribe To Our Newsletter & Stay Updated
